{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:31Z","timestamp":1787026411220,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor patients with type 2 diabetes mellitus (T2DM) have a more immunosuppressive tumor microenvironment and weaker T-cell immune response to tumors within the tumor compared to non-T2DM patients when treated with immune checkpoint inhibitors (ICIs).In addition, high blood glucose levels may promote tumor immune escape. These factors may lead to a poor response to ICIs treatment in tumor patients with T2DM, affecting treatment prognosis. Although some studies have explored the association between tumor patients with T2DM and the prognosis of ICIs treatment, there is still controversy. Therefore, this study systematically evaluated the impact of T2DM on the prognosis of ICIs treatment in tumor patients through a meta-analysis, aiming to provide more accurate guidance for clinical practice and optimize the treatment strategy for tumor patients with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Web of Science, CNKI, and Wanfang Database to collect studies published from the database establishment to January 2026 that investigated the association between tumor patients with T2DM and the prognosis of ICIs treatment. The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) was used to evaluate the risk of bias. The pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to assess the association between tumor patients with T2DM and the prognosis of ICIs treatment. The primary outcomes included overall survival (OS) and progression-free survival (PFS). Meta-analysis was conducted using RevMan 5.3 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six studies were included, involving 1,225 participants. The meta-analysis showed that patients with T2DM who received ICIs treatment had poorer OS (HR = 1.49, 95%CI:1.25-1.77, P &amp;lt; 0.00001) and PFS(HR = 1.38, 95%CI:1.04-1.83, P = 0.03).Subgroup analyses indicated that regardless of sample size (&amp;lt;200 vs &amp;gt;200) or type of survival analysis (univariate vs multivariate), patients with tumors and T2DM who received ICI treatment were consistently associated with poorer OS. Regarding PFS, a worse outcome was observed in T2DM patients when the sample size was less than 200 or when univariate analysis was applied. However, no significant statistical difference in PFS was found between non-T2DM and T2DM patients treated with ICIs when the sample size exceeded 200 or when multivariate analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the current limited evidence, this meta-analysis suggests that T2DM may be associated with poor OS in lung cancer patients treated with ICIs. However, due to the small number of included studies, limited sample size, inherent bias risks of the retrospective design, heterogeneity of tumor types, and the instability of PFS results. The conclusion of this study belongs to the \u2018put forward hypothesis\u2019 level and is not yet sufficient to support clinical practice recommendations. The current evidence cannot determine whether glycemic control can improve the efficacy of ICIs. Future studies need to verify this finding through large-sample, prospective cohort studies and clarify the independent impact of glycemic control levels on the efficacy of ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1808976","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:03Z","timestamp":1778473443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Linlin","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Comprehensive Ward, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Scientific Research, The Shapingba Hospital, Chongqing University (People\u2019s Hospital of Shapingba District, Chongqing)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"General Practice, The Shapingba Hospital, Chongqing University (People\u2019s Hospital of Shapingba District, Chongqing)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Ward, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70011","article-title":"Cancer treatment and survivorship statistic","volume":"75","author":"Wagle","year":"2025","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae135","article-title":"Prevalence of cancer survivors in the United States","volume":"116","author":"Tonorezos","year":"2024","journal-title":"J Natl Cancer Institute"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1707622","article-title":"Efficacy of tace plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"15","author":"Ye","year":"2025","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685963","article-title":"Enhanced efficacy of lung cancer treatment with radiotherapy and immune checkpoint inhibitors without increased pneumonia risk: A systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-025-15310-6","article-title":"Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: A meta-analysis","volume":"26","author":"Fu","year":"2025","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-025-04277-9","article-title":"Efficacy and safety of sequential versus concurrent administration of immune checkpoint inhibitors with radiotherapy in solid tumors: A systematic review and network meta-analysis","volume":"75","author":"Baek","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: Mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: New pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.03.011","article-title":"Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk","volume":"60","author":"La Vecchia","year":"2011","journal-title":"Metab Clin Exp"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1677\/erc-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocrine-Related Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14223","article-title":"Impact of diabetes on the prognosis of patients with oral and oropharyngeal cancer: A meta-analysis","volume":"15","author":"Xu","year":"2024","journal-title":"J Diabetes Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5761\/atcs.ra.19-00170","article-title":"The effect of diabetes mellitus on prognosis of patients with non-small-cell lung cancer: A systematic review and meta-analysis","volume":"26","author":"Bi","year":"2020","journal-title":"Ann Thorac Cardiovasc Surgery: Off J Assoc Thorac Cardiovasc Surgeons Asia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01337-2","article-title":"The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: A meta-analysis","volume":"56","author":"Ma","year":"2019","journal-title":"Acta Diabetologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176068","article-title":"The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies","volume":"12","author":"Zhu","year":"2017","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-Pd-1\/anti-Ctla-4) in metastatic Malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2525-1","article-title":"Diabetes and cancer (1): Evaluating the temporal relationship between type 2 diabetes and cancer incidence","volume":"55","author":"Johnson","year":"2012","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000516671","article-title":"The relationship of diabetes mellitus to efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"99","author":"Jacobi","year":"2021","journal-title":"Oncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-302","article-title":"Effect of type 2 diabetes mellitus on systemic treatment for advanced non-small cell lung cancer","volume":"14","author":"Kato","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34918","article-title":"Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer","volume":"129","author":"Leshem","year":"2023","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12967-023-04607-4","article-title":"The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab","volume":"21","author":"Mallardo","year":"2023","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12467\/j.issn.2096-3882.20240522","article-title":"Effect of type 2 diabetes on the clinical efficacy of immunotherapy in advanced non-small cell lung cancer","volume":"45","author":"Rong","year":"2025","journal-title":"J Xuzhou Med Univ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s289446","article-title":"Pre-existing diabetes limits survival rate after immune checkpoint inhibitor treatment for advanced lung cancer: A retrospective study in Japan","volume":"14","author":"Hisanaga","year":"2021","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/HM9.0000000000000172","article-title":"Effectiveness of acupuncture in managing aromatase inhibitor-related arthralgia in breast cancer: A systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2025","journal-title":"Acupuncture Herbal Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: Development of the prisma 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/hm9.0000000000000093","article-title":"Efficacy and safety of acupuncture in treating low back and pelvic girdle pain during pregnancy: A systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Zhang","year":"2024","journal-title":"Acupuncture Herbal Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000565","article-title":"Association between metformin use and mortality among individuals with non-small cell lung cancer receiving immune checkpoint inhibitors: A retrospective cohort study","volume":"48","author":"Sun","year":"2025","journal-title":"J Immunotherapy (Hagerstown Md: 1997)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.cir-16-0103","article-title":"Efficacy of Pd-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3116","article-title":"Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer","volume":"29","author":"Cortellini","year":"2023","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.01.001","article-title":"High glucose and hyperglycemic sera from type 2 diabetic patients impair dc differentiation by inducing ros and activating wnt\/\u03b2-catenin and p38 mapk","volume":"1862","author":"Gilardini Montani","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13187","article-title":"Functional status of immune cells in patients with long-lasting type 2 diabetes mellitus","volume":"194","author":"Nam","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.237123","article-title":"Gr-1+ cd11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity","volume":"286","author":"Xia","year":"2011","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmy014","article-title":"Myeloid-derived suppressor cells suppress cd4+ t cell activity and prevent the development of type 2 diabetes","volume":"50","author":"Wang","year":"2018","journal-title":"Acta Biochim Biophys Sin"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002615","article-title":"Elevated proinflammatory cytokine production by a skewed t cell compartment requires monocytes and promotes inflammation in type 2 diabetes","volume":"186","author":"Jagannathan-Bogdan","year":"2011","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2025.02.014","article-title":"Diabetes can impact cellular immunity in solid tumors","volume":"46","author":"Garstka","year":"2025","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0209","article-title":"Hyperglycemia and not hyperinsulinemia mediates diabetes-induced memory cd8 t-cell dysfunction","volume":"71","author":"Kavazovi\u0107","year":"2022","journal-title":"Diabetes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1218","article-title":"Senescent t cells predict the development of hyperglycemia in humans","volume":"68","author":"Lee","year":"2019","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13046-019-1209-9","article-title":"High glucose promotes pancreatic cancer cells to escape from immune surveillance via ampk-bmi1-gata2-mica\/b pathway","volume":"38","author":"Duan","year":"2019","journal-title":"J Exp Clin Cancer Research: CR"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215840110","article-title":"B cells promote inflammation in obesity and type 2 diabetes through regulation of t-cell function and an inflammatory cytokine profile","volume":"110","author":"DeFuria","year":"2013","journal-title":"PNAS"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1808976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:07Z","timestamp":1778473447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1808976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1808976"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1808976","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1808976"}}